Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Inclusion Criteria:

* Older than 18 years of age.
* Confirmed diagnosis of active progressive multiple myeloma
* History of \> 2 prior cytotoxic treatment regimens. Bone marrow transplantation will be considered as one regimen.
* Current measurable disease based on serum and/or urine M protein and/or measurable plasmacytoma.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Absolute neutrophil count (ANC) \> 1,500 mm3
* Platelets \> 100,000 mm3
* Serum creatinine \< 1.5 upper limit of normal (ULN)
* Serum bilirubin \< 1.5 ULN
* AST/AGOT and ALT/SGPT \< 3.0 ULN
* Life expectancy \> 12 weeks

Exclusion Criteria:

* Chemotherapy \< 3 weeks prior to registration.
* Biologic or immunotherapy \< 2 weeks prior to registration
* Full field radiotherapy \< 4 weeks or limited field radiotherapy \< 2 weeks prior to registration.
* History or presence of central nervous system (CNS) disease
* History of leukemia
* History of another primary malignancy with the exception of inactive basal or squamous cell carcinoma of the skin
* Major surgery \< 4 weeks prior to registration
* Prior therapy with anti-vascular endothelial growth factor (VEGF) agents excluding thalidomide, Revimid, velcade and arsenic trioxide
* Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
* Pleural effusion or ascites that cause respiratory compromise
* Female patients that are pregnant or breast feeding
* Uncontrolled high blood pressure, history of labile hypertension or history of poor compliance with an antihypertensive regimen
* Unstable angina pectoris
* Symptomatic congestive heart failure
* Myocardial infarction \< 6 months prior to registration
* Serious uncontrolled cardiac arrhythmia
* Uncontrolled diabetes
* Active or uncontrolled infection
* Acute or chronic liver disease
* Impairment of gastrointestinal (GI) function or GI disease
* Confirmed HIV infection